BONESUPPORT HOLDING AB (publ) – Q3 2017 Interim Report – invitation to conference call and webcast
Lund, Sweden, 08:00 CEST 19 October 2017 – BONESUPPORT™ an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, will publish its Q3 2017 Interim Report on Thursday 2 November 2017 at 08.00am CEST.
The Company will also host a conference call and an online presentation on the same day at 10am CEST.
The dial-in numbers for the conference call are:
UK: +442030089806
SE: +46850639549
US: +18558315945
The presentation will also be webcast and can be accessed from the following web address:
http://www.financialhearings.com/event/10531
Hosts: Richard Davies, CEO, and Björn Westberg, CFO
Contact Information
BONESUPPORT AB
Richard Davies, CEO
Tel: +46 (0) 46 286 53 71
Björn Westberg, CFO
Tel: +46 (0) 46 286 53 60
Email: ir@bonesupport.com
Citigate Dewe Rogerson
David Dible, Pip Batty, Marine Perrier
+44 (0)20 7638 9571
Notes to Editor
About BONESUPPORT™
BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void. BONESUPPORT’s marketed bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary CERAMENT technology platform.
The Company’s products are targeting a large addressable market opportunity across trauma, chronic
osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected
diabetic foot.
BONESUPPORT’s total sales increased from SEK 41 million in 2014 to SEK 105 million in 2016, representing a compound annual growth rate of 60 percent. The Company’s financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.
The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.
BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at www.bonesupport.com
*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States.
BONESUPPORT™ and CERAMENT® are registered trademarks.